Health & Biotech
Long Shortz with Island Pharmaceuticals: Trial success with dengue fever drug
Imricor performs first atrial flutter ablation at Swiss hospital
Health Check: ASX sleep company emerges from slumber with a revenue and earnings upgrade
Orthocell appoints distributor for nerve repair product Remplir in Singapore
Aroa product revenue up 27pc as Myriad sales drive growth
Biocurious: Stiff competition aside, cryopreserver Vitrafy has the ingredients for success
Health Check: Biotech double-banger breaks the IPO drought
Dr Boreham’s Crucible: The rise and rise of LTR Pharma
Renerve all set to become only the second nerve-repair stock on the ASX
Health Check: Chinese consumer market is a thing of beauty, says EZZ Life Sciences
Scott Power: Global health markets wobble as Trump picks RFK Jr for top health role
Tryptamine’s world-first psilocin based IV-infusion meets key objectives in phase 1b study
‘Moving ahead with vigour’: Rhythm raises $3.5m for 2025 cancer test launch
Health Check: Mayne Pharma and Acrux are on a drug expansion drive, generically speaking
ASX health stocks fighting superbugs to save lives
Medical imaging stock Singular Health seals US deal and locks in $3.7m raise
Health Check: Painchek strives to Make American Aged Folk Comfortable Again
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.